Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level

• Ninon Taylor ,

  Contributed equally to this work with: Ninon Taylor, Katharina Grabmeier-Pfistershammer

  * E-mail: n.taylor@salk.at (NT); katharina.pfistershammer@meduniwien.ac.at (KG)

  Affiliation Department of Internal Medicine III, Paracelsus Medical University, Salzburg, Austria

  ⨯
• Katharina Grabmeier-Pfistershammer ,

  Contributed equally to this work with: Ninon Taylor, Katharina Grabmeier-Pfistershammer

  * E-mail: n.taylor@salk.at (NT); katharina.pfistershammer@meduniwien.ac.at (KG)

  Affiliation Department of Dermatology, Vienna Medical University, Vienna, Austria

  ⨯
• Alexander Egle,

  Affiliation Department of Internal Medicine III, Paracelsus Medical University, Salzburg, Austria

  ⨯
• Richard Greil,

  Affiliation Department of Internal Medicine III, Paracelsus Medical University, Salzburg, Austria

  ⨯
• Armin Rieger,

  Affiliation Department of Dermatology, Vienna Medical University, Vienna, Austria

  ⨯
• Bruno Ledergerber,

  Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland

  ⨯
• Hannes Oberkofler

  Affiliation Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria

  ⨯